@article{MTMT:34813506,
	title = {Antitrombin-III-deficites gravidák - kezelési lehetőségek},
	url = {https://m2.mtmt.hu/api/publication/34813506},
	author = {Bíró, Krisztina and Ujhelyi, Zoltán and Schlammadinger, Ágota and Rázsó, Katalin and Buchholcz, Gyula and Boda, Zoltán},
	journal-iso = {GYÓGYSZERÉSZET},
	journal = {GYÓGYSZERÉSZET},
	volume = {68},
	unique-id = {34813506},
	issn = {0017-6036},
	year = {2024},
	pages = {62-66},
	orcid-numbers = {Bíró, Krisztina/0000-0002-2070-0608}
}

@article{MTMT:34722559,
	title = {Direct modulation of TRPM8 ion channels by rapamycin and analog macrolide immunosuppressants},
	url = {https://m2.mtmt.hu/api/publication/34722559},
	author = {Tóth, Balázs István and Bahar, Bazeli and Annelies, Janssens and Lisztes, Erika and Racskó, Márk and Kelemen, Balázs and Herczeg, Mihály and Nagy, Tamás Milán and E Kövér, Katalin and Argha, Mitra and Attila, Borics and Bíró, Tamás and Thomas, Voets},
	journal-iso = {ELIFE},
	journal = {ELIFE},
	unique-id = {34722559},
	issn = {2050-084X},
	year = {2024},
	eissn = {2050-084X},
	orcid-numbers = {Herczeg, Mihály/0000-0002-7938-9789}
}

@book{MTMT:34688590,
	title = {Laboratóriumi Diagnosztikai Gyakorlatok},
	url = {https://m2.mtmt.hu/api/publication/34688590},
	isbn = {9789636151065},
	editor = {Kappelmayer, János},
	publisher = {Debreceni Egyetemi Kiadó},
	unique-id = {34688590},
	year = {2023}
}

@article{MTMT:34517633,
	title = {Fiatal férfi szisztémás tünetekkel : Behçet szindróma vagy ANCA vasculitis?},
	url = {https://m2.mtmt.hu/api/publication/34517633},
	author = {Markóth, Csilla and Nagy-Vincze, Melinda and Bidiga, László and Remenyik, Éva and Balla, József and Mátyus, János},
	journal-iso = {HYPERTONIA NEPHROLOGIA},
	journal = {HYPERTONIA ÉS NEPHROLOGIA},
	volume = {27},
	unique-id = {34517633},
	issn = {1418-477X},
	year = {2023},
	eissn = {2498-6259},
	pages = {35}
}

@article{MTMT:34486449,
	title = {Merre tart a hazai experimentális kardiológia?},
	url = {https://m2.mtmt.hu/api/publication/34486449},
	author = {Baczkó, István and Papp, Zoltán},
	journal-iso = {CARDIOL HUNG},
	journal = {CARDIOLOGIA HUNGARICA},
	volume = {53},
	unique-id = {34486449},
	issn = {0133-5596},
	year = {2023},
	eissn = {1588-0230},
	pages = {414},
	orcid-numbers = {Baczkó, István/0000-0002-9588-0797}
}

@article{MTMT:34400338,
	title = {A kardiális miozinaktivátorok klinikai alkalmazhatósága a preklinikai vizsgálatok tükrében [= Clinical applications of cardiac myosin activators in the light of preclinical studies]},
	url = {https://m2.mtmt.hu/api/publication/34400338},
	author = {Ráduly, Arnold Péter and Sárkány, Fruzsina and Kovács, Máté Balázs and Juhász, Béla and Horváth, Balázs and Szentandrássy, Norbert and Nánási, Péter Pál and Édes, István and Csanádi, Zoltán and Tóth, Attila and Papp, Zoltán and Priksz, Dániel and Borbély, Attila},
	doi = {10.26430/CHUNGARICA.2023.53.5.476},
	journal-iso = {CARDIOL HUNG},
	journal = {CARDIOLOGIA HUNGARICA},
	volume = {53},
	unique-id = {34400338},
	issn = {0133-5596},
	abstract = {A csökkent ejekciós frakciójú szívelégtelenség (HFrEF) gyógyszeres kezelésében az utóbbi évtizedben jelentős fejlődés következett be. A kórkép patomechanizmusának középpontjában álló kontraktilis diszfunkciót direkten javító, úgynevezett pozitív inotróp szerek azonban továbbra sem hoztak átütő sikert. Az ideális pozitív inotróp szer nem fokozza a myocardium energiaigényét és oxigénfelhasználását. Az eddig használt gyógyszerek sajnos maradéktalanul nem tudtak megfelelni ezeknek az elvárásoknak. Az aktin-miozin-interakció direkt modulálása miozinaktivátorokkal egy új terápiás célpont a kontrakciós erő fokozására, a korábbi szerekre jellemző káros mellékhatások nélkül. Klinikai vizsgálatokban az első ilyen gyógyszer, az omecamtiv-mecarbil (OM) – a III. fázis vizsgálatok kezdeti pozitív eredményei ellenére – megfelelő hatékonyság hiánya miatt mégsem került bevezetésre a klinikai gyakorlatba. Ezen vegyület alkalmazhatóságát korlátozó tényezőket számos preklinikai tanulmány vizsgálta. Az OM sikertelensége ugyanakkor egy új típusú miozinaktivátor, a danicamtiv kifejlesztését is potencírozta. A danicamtivval kapcsolatos preklinikai és klinikai vizsgálatok jelenleg még korlátozott számban érhetőek el. Az eddigi eredmények biztatóbbak a danicamtivval kapcsolatban, azonban ennek megerősítésére még számos vizsgálatra van szükség. Feltételezhetően mindkét gyógyszerjelölt jövőbeli alkalmazhatóságát diasztolés diszfunkciót okozó hatásuk korlátozhatja.
		
		Summary:
		There have been significant advances in the management of heart failure with reduced ejection fraction (HFrEF) over the last decade. However, the so-called positive inotropic agents, which directly correct the contractile dysfunction at the heart of the pathomechanism of the disease, have still not been a resounding success. The ideal positive inotropic agent does not increase myocardial energy demand and oxygen consumption. Unfortunately, the drugs used so far have not fully met these requirements. Direct modulation of the actin-myosin interaction by myosin activators is a new therapeutic target to enhance contractile force without the adverse side effects typical of previous agents. In clinical trials, the first such drug, omecamtiv mecarbil (OM), has not been introduced into clinical practice due to lack of adequate efficacy, despite initial positive results in phase III trials. Several preclinical studies have investigated the limiting factors for the applicability of this compound. However, the failure of OM has also stimulated the development of a new type of myosin activator, danicamtiv. Preclinical and clinical studies on danicamtiv are currently limited. The results to date are more encouraging for danicamtiv, but many more studies are needed to confirm this. Presumably, the future applicability of both candidates may be limited by their adverse effects on diastolic function.},
	keywords = {Myosin activators; Danicamtiv; omecamtiv-mecarbil; pozitív inotrópia; diasztolés diszfunkció; positive inotropy; miozinaktivátor; diastolic dyfunction},
	year = {2023},
	eissn = {1588-0230},
	pages = {476-483},
	orcid-numbers = {Horváth, Balázs/0000-0003-2562-8446; Szentandrássy, Norbert/0000-0003-0197-9567}
}

@article{MTMT:34397560,
	title = {Immunellenőrzőpont-gátlók a cervix- és endometriumcarcinoma kezelésének gyakorlatában - összefoglaló a Debreceni Egyetem Nőgyógyászati Onkológiai Tanszék betegeinek terápiás eredményeiről},
	url = {https://m2.mtmt.hu/api/publication/34397560},
	author = {Árokszállási, Anita and Molnár, Szabolcs and Damjanovich, Péter Gábor and Lukács, János and Kovács, Ilona and Molnár, Sarolta and Póka, Róbert and Hernádi, Zoltán and Lampé, Rudolf and Krasznai, Zoárd Tibor},
	journal-iso = {MAGYAR ONKOLÓGIA},
	journal = {MAGYAR ONKOLÓGIA},
	volume = {67},
	unique-id = {34397560},
	issn = {0025-0244},
	year = {2023},
	eissn = {2060-0399},
	pages = {9-10},
	orcid-numbers = {Lampé, Rudolf/0000-0002-8230-7692}
}

@article{MTMT:34100454,
	title = {Biomechanical Comparison of the Roof Step Cut Technique with the Bulk Bone Graft Technique During Total Hip Arthroplasty for Hip Dysplasia : a Finite Element Analysis},
	url = {https://m2.mtmt.hu/api/publication/34100454},
	author = {Zhang, Lei and Alkentar, Rashwan and Manó, Sándor and Szabó, János and Mankovits, Tamás and Csernátony, Zoltán},
	doi = {10.55095/ACHOT2023/036},
	journal-iso = {ACTA CHIR ORTHOPAED TRAUMATOL CECHOSLOVACA},
	journal = {ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA},
	volume = {90},
	unique-id = {34100454},
	issn = {0001-5415},
	year = {2023},
	pages = {329-341},
	orcid-numbers = {Alkentar, Rashwan/0000-0002-9866-4555; Mankovits, Tamás/0000-0001-7245-6443}
}

@article{MTMT:34034279,
	title = {PARP2 promotes inflammation in psoriasis by modulating estradiol biosynthesis in keratinocytes},
	url = {https://m2.mtmt.hu/api/publication/34034279},
	author = {Antal, Dóra and Pór, Ágnes and Kovács, Ilona and Dull, Katalin and Póliska, Szilárd and Ujlaki, Gyula and Demény, Máté Ágoston and Szöllősi, Attila and Kiss, Borbála and Szegedi, Andrea and Bay, Péter and Szántó, Magdolna},
	doi = {10.1007/s00109-023-02338-z},
	journal-iso = {J MOL MED-JMM},
	journal = {JOURNAL OF MOLECULAR MEDICINE-JMM},
	volume = {101},
	unique-id = {34034279},
	issn = {0946-2716},
	year = {2023},
	eissn = {1432-1440},
	pages = {987-999},
	orcid-numbers = {Pór, Ágnes/0000-0002-2945-0684; Kovács, Ilona/0000-0003-0629-5615; Dull, Katalin/0000-0001-5594-0364; Póliska, Szilárd/0000-0002-9722-251X; Szöllősi, Attila/0000-0001-6046-8236; Kiss, Borbála/0000-0002-6076-9984; Szegedi, Andrea/0000-0003-2109-9014}
}

@article{MTMT:33938541,
	title = {Development and Evaluation of an FDM Printed Nasal Device for CPZ Solid Nanoparticles},
	url = {https://m2.mtmt.hu/api/publication/33938541},
	author = {To Quoc, Thinh and Bíró, Krisztina and Pető, Ágota and Kósa, Dóra and Sinka, Dávid and Lekli, István and Kiss, Attila and Budai, István and Béresová, Monika and Vecsernyés, Miklós and Siposné Fehér, Pálma and Bácskay, Ildikó and Ujhelyi, Zoltán},
	doi = {10.3390/molecules28114406},
	journal-iso = {MOLECULES},
	journal = {MOLECULES},
	volume = {28},
	unique-id = {33938541},
	issn = {1420-3049},
	abstract = {Nasal drug delivery has been a focus of scientific interest for decades. A number of drug delivery systems and devices are available and have been highly successful in providing better and more comfortable therapy. The benefits of nasal drug delivery are not in question. The nasal surface provides an excellent context for the targeted delivery of active substances. In addition to the large nasal surface area and intensive absorption, the active substances delivered through the nose overcome the blood–brain barrier and can be delivered directly to the central nervous system. Formulations for nasal administration are typically solutions or liquid dispersed systems such as emulsions or suspensions. Formulation techniques for nanostructures have recently undergone intensive development. Solid-phase heterogeneous dispersed systems represent a new direction in pharmaceutical formulations. The wide range of possible examples and the variety of excipients allow for the delivery of a wide range of active ingredients. The aim of our experimental work was to develop a solid drug delivery system that possesses all of the above-mentioned advantageous properties. In developing solid nanosystems, we not only exploited the advantages of size but also the adhesive and penetration-enhancing properties of excipients. During formulation, several amphiphilic compounds with adhesion properties and penetration enhancing effects were incorporated. We used chlorpromazine (CPZ), which is mainly used in the treatment of psychotic disorders such as schizophrenia and bipolar disorder. Chlorpromazine has been previously investigated by our team in other projects. With the availability of previous methods, the analytical characterization of the drug was carried out effectively. Due to the frequent and severe side effects of the drug, the need for therapeutic dose reduction is indisputable. In this series of experiments, we succeeded in constructing drug delivery systems. Finely divided Na nanoparticles were formed using a Büchi B90 nanospray dryer. An important step in the development of the drug carrier was the selection of suitable inert carrier compounds. Particle size determination and particle size distribution analysis were performed to characterize the prepared nanostructures. As safety is the most important aspect of any drug formulation, all components and systems were tested with different biocompatibility assays. The tests performed demonstrated the safe applicability of our systems. The bioavailability of chlorpromazine was studied as a function of the ratio of the active ingredient administered nasally and intravenously. As described above, most nasal formulations are liquids, but our system is solid, so there is currently no tool available to accurately target this system. As a supplement of the project, a nasal dosing device was developed, corresponding to the anatomical structure; a prototype of the device was made using 3D FDM technology. Our results lay the foundation for the design and industrial scaling of a new approach to the design and production of a high-bioavailability nasal medicinal product.},
	keywords = {chlorpromazine; Nanostructures; spray drying; TEER; penetration enhancers; MTT test; cytotoxicity investigation; RPMI cells},
	year = {2023},
	eissn = {1420-3049},
	orcid-numbers = {Kiss, Attila/0000-0003-3601-5143; Budai, István/0000-0002-8966-3817; Béresová, Monika/0000-0001-8610-3788; Bácskay, Ildikó/0000-0001-8663-2890}
}